HemaQuest is a Seattle-based biopharmaceutical company developing proprietary small molecules targeting specific genes that enable the treatment of serious and life threatening hematologic disorders. Currently, the Company has two therapeutics in Phase 2 clinical development - HQK-1001 for hemoglobin disorders, such as sickle cell disease, and HQK-1004 for viral-related cancers. It was founded in late 2007 by leading hematologists with funding from top tier investors, including De Novo Ventures, Forward Ventures, and Lilly Ventures.